Abstract:Background: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia. Methods: In the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs pravastatin for Dyslipidemia) randomised, double-blind, active-controlled, phase 4 trial (INTREPID, we recruited adults aged 18-70 years with controlled HIV (with CD4 counts >200 cells per μL and HIV-1 RNA <200 copies per mL) on antiretroviral therapy for at least 6 months and dyslipidaemia (LDL cholesterol 3·4-5·7 mmol/L and triglycerides ≤4·5 mmol/L) from 45 sites in the USA and Puerto Rico. Patients being treated with darunavir, or who had homozygous familial hypercholesterolaemia or any condition causing secondary dyslipidaemia, or a history of statin intolerance, diabetes, or coronary artery disease were not eligible. We randomly assigned patients (1:1) to pitavastatin 4 mg or pravastatin 40 mg with matching placebos once daily orally for 12 weeks, followed by a 40 week safety extension. Randomisation was stratified by viral hepatitis B or C coinfection and computer-generated. Investigators, patients, study staff, and those assessing outcomes were masked to treatment group. The primary endpoint was percentage change in fasting serum LDL cholesterol from baseline to week 12 and the primary efficacy analysis was done in the modified intention-to-treat population. The safety analysis included all patients who took at least one dose of study medication. This study is registered with ClinicalTrials.gov, number NCT01301066. Findings: Between Feb 23, 2011, and March 29, 2013, we randomly assigned 252 patients to the pitavastatin (n=126) or pravastatin group (n=126). LDL cholesterol reduction was 31·1% with pitavastatin and 20·9% with pravastatin (least squares mean difference -9·8%, 95% CI -13·8 to -5·9; p<0·0001) at 12 weeks. At week 52, four patients (3%) in the pitavastatin group and six (5%) in the pravastatin group had virological failure, with no significant difference between treatments. Both treatments had neutral effects on glucose metabolism parameters. 85 patients treated with pitavastatin (68%) and 88 patients treated with pravastatin (70%) reported treatment-emergent adverse events, and these caused study discontinuation in six patients (5%) versus five patients (4%). No serious adverse event occurred in more than one participant and none were treatment-related according to investigator assessment. The most common treatment-emergent adverse events were diarrhoea in the pitavastatin group (n=12, 10%) and upper respiratory tract infection in the pravastatin group (n=14, 11%). 11 treatment-emergent serious adverse events were noted in seven patients (6%) in the pitavastatin group (atrial septal defect, chronic obstructive pulmonary disease, chest pain, diverticulitis, enterovesical fistula, gastroenteritis, viral gastroenteritis, herpes dermatitis, multiple fractures, respiratory failure, and transient ischaemic attack) and four events in three patients (2%) in the pravastatin group (cerebrovascular accident, arteriosclerosis coronary artery, myocardial infraction, and muscle haemorrhage). In the pravastatin treatment group, one additional patient discontinued due to an adverse event (prostate cancer that was diagnosed during the screening period, 42 days before first dose of study treatment, and therefore was not a treatment-emergent adverse event). Interpretation: The INTREPID results support guideline recommendations for pitavastatin as a preferred drug in the treatment of dyslipidaemia in people with HIV. Funding: Kowa Pharmaceuticals America and Eli Lilly and Company.

[Safety and Efficacy of Pitavastatin in Patients with Hypercholesterolemia: a Multicenter Study].

Pharmacokinetics and Safety of Pitavastatin Calcium Tablets in Chinese Healthy Volunteers after a Single Oral Dose Administration

The Effect of Pitavastatin on Blood Glucose and Its Efficacy in Diabetic Patients with Hypercholesterolemia

The efficacy and safety of pravastatin in treatment of hypercholesterolemia

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

Effect and Risk Factors of Pitavastatin on High Sensitivity C-reactive Protein in Patients with Hypercholesterolemia: a Multilevel Models Analysis

Comparison of Effects and Safety of Coenzyme A and Fenofibrate in Patients with Dyslipidemia

Efficacy and Safety of Hybutimibe in Combination with Atorvastatin for Treatment of Hypercholesteremia among Patients with Atherosclerotic Cardiovascular Disease Risk Equivalent: A Multicenter, Randomized, Double-Blinded Phase III Study.

Comparative study of pitavastatin and atorvastatin on efficacy and safety in patients with ischemic stroke

Atorvastatin Decreased Low Density Lipoprotein Level and Improved Coronary Artery Lesion in Patients after Percutaneous Coronary Intervention

Pitavastatin calcium significantly improves glucose and lipid metabolism of patients with coronary atherosclerosis and reduces the occurrence of adverse cardiovascular events

Multi-center Study of Efficacy and Safety of Atorvastatin 20 Mg in Chinese Coronary Heart Disease Patients with Hyperlipidemia

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

Pitavastatin: finding its place in therapy

Effectiveness and Safety of Simvastatin 40 mg Daily Use in Treatment of Coronary Heart Disease

Meta-analysis of the Efficacy and Safety of Simvastatin vs. Pravastatin in the Treatment of Hyperlipidemia

Effect of pitavastatin and atorvastatin on regulation of lipid in ischemic stroke patients

Short-term efficacy of different statins in treatment of patients with nonalcoholic fatty liver disease and hyperlipidaemia

Efficacy and safety comparison of different statins in elderly patients

Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial